291 related articles for article (PubMed ID: 11148863)
1. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
Greven J; Gabriëls G
Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
[TBL] [Abstract][Full Text] [Related]
2. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
[TBL] [Abstract][Full Text] [Related]
3. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
4. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
6. Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.
Mose FH; Jensen JM; Therwani S; Mortensen J; Hansen AB; Bech JN; Pedersen EB
Br J Clin Pharmacol; 2015 Sep; 80(3):425-35. PubMed ID: 25778445
[TBL] [Abstract][Full Text] [Related]
7. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
8. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney.
Kakoki M; Hirata Y; Hayakawa H; Nishimatsu H; Suzuki Y; Nagata D; Suzuki E; Kikuchi K; Nagano T; Omata M
Hypertension; 1999 Jan; 33(1 Pt 2):467-71. PubMed ID: 9931149
[TBL] [Abstract][Full Text] [Related]
9. Effects of nebivolol on human platelet aggregation.
Falciani M; Rinaldi B; D'Agostino B; Mazzeo F; Rossi S; Nobili B; Rossi F; Filippelli A
J Cardiovasc Pharmacol; 2001 Dec; 38(6):922-9. PubMed ID: 11707696
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol-induced vasodilation of renal afferent arterioles involves β3-adrenergic receptor and nitric oxide synthase activation.
Feng MG; Prieto MC; Navar LG
Am J Physiol Renal Physiol; 2012 Sep; 303(5):F775-82. PubMed ID: 22674024
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol ameliorates nitric oxide deficient hypertension.
Fortepiani LA; Ortíz MC; Atucha NM; García-Estañ J
ScientificWorldJournal; 2002 Jun; 2():1676-84. PubMed ID: 12806161
[TBL] [Abstract][Full Text] [Related]
12. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol.
Parenti A; Filippi S; Amerini S; Granger HJ; Fazzini A; Ledda F
J Pharmacol Exp Ther; 2000 Feb; 292(2):698-703. PubMed ID: 10640308
[TBL] [Abstract][Full Text] [Related]
13. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension.
Patterson ME; Mouton CR; Mullins JJ; Mitchell KD
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F754-9. PubMed ID: 15900020
[TBL] [Abstract][Full Text] [Related]
14. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
15. Effect of the novel T-selective calcium channel antagonist mibefradil on kidney function in comparison with amlodipine.
Greven J
Arzneimittelforschung; 1998 Aug; 48(8):806-10. PubMed ID: 9748707
[TBL] [Abstract][Full Text] [Related]
16. The effect of chloroquine on renal function and vasopressin secretion: a nitric oxide-dependent effect.
Ahmed MH; Ashton N; Balment RJ
J Pharmacol Exp Ther; 2003 Jan; 304(1):156-61. PubMed ID: 12490586
[TBL] [Abstract][Full Text] [Related]
17. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
18. Effects of prostaglandins and nitric oxide on the renal effects of angiotensin II in the anaesthetized rat.
Clayton JS; Clark KL; Johns EJ; Drew GM
Br J Pharmacol; 1998 Aug; 124(7):1467-74. PubMed ID: 9723960
[TBL] [Abstract][Full Text] [Related]
19. Neither K+ channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries.
Wang Y; Zhang M; Liu Y; Li J; Song E; Niu L; Cheng N
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):332-8. PubMed ID: 19903983
[TBL] [Abstract][Full Text] [Related]
20. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
Prisant LM
J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]